Digitoxin
A cardiac glycoside derived from the foxglove plant used to treat heart failure and atrial fibrillation by increasing the strength of heart contractions and slowing heart rate. It has a very long half-life of several days and is metabolized primarily by the liver. It has a narrow therapeutic window, meaning the difference between an effective dose and a toxic dose is small.
Molecular Weight
764.9000 g/mol
LogP
2.30
TPSA
183.00 Ų
Lipinski RO5
Fail
Therapeutic Areas
Mechanism of Action
Inhibits the sodium-potassium ATPase pump in cardiac myocytes, increasing intracellular sodium and subsequently calcium via the sodium-calcium exchanger. This enhances cardiac contractility (positive inotropic effect).
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits the sodium-potassium ATPase pump in cardiac myocytes, increasing intracellular sodium and subsequently calcium via the sodium-calcium exchanger. This enhances cardiac contractility (positive inotropic effect).
2D Structure
Cite this structure
Embed this structure
SMILES
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
InChI
InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1
Molecular Formula
C41H64O13
HBD / HBA
5 / 13
Rotatable Bonds
7
Heavy Atoms
54
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A cardiac glycoside derived from the foxglove plant used to treat heart failure and atrial fibrillation by increasing the strength of heart contractions and slowing heart rate. It has a very long half-life of several days and is metabolized primarily by the liver. It has a narrow therapeutic window, meaning the difference between an effective dose and a toxic dose is small.
Inhibits the sodium-potassium ATPase pump in cardiac myocytes, increasing intracellular sodium and subsequently calcium via the sodium-calcium exchanger. This enhances cardiac contractility (positive inotropic effect).
Yes, Digitoxin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL254219. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 441207. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="digitoxin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/digitoxin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/digitoxin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/digitoxin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="digitoxin"></drugfyi-drug>